Status:

COMPLETED

Post-Market Clinical Study of the PanOptix Intraocular Lens (IOL) in a Chinese Population

Lead Sponsor:

Alcon Research

Conditions:

Aphakia

Presbyopia

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The primary objective of this clinical study is to assess the clinical performance of the PanOptix IOL in a Chinese population.

Detailed Description

In this clinical study, subjects will be implanted with the PanOptix IOL in both eyes. The second eye surgery will occur 7-28 days after the first eye. A total of 11 scheduled visits are planned, incl...

Eligibility Criteria

Inclusion

  • Key
  • Able to comprehend and sign an informed consent form;
  • Able to complete all study visits required in the protocol;
  • Chinese; diagnosed with cataracts in both eyes;
  • Planned bilateral cataract removal by routine phacoemulsification;
  • Pre-operative regular corneal astigmatism of less than 1.0 diopter (D);
  • Pre-operative best corrected distance visual acuity (BCDVA) worse than or equal to 0.3 LogMAR in each eye;
  • Potential postoperative best corrected distance visual acuity (BCDVA) of 0.3 logMAR or better in both eyes based on the investigator expert medical opinion.
  • Other protocol-specified inclusion criteria may apply.
  • Key

Exclusion

  • Glaucoma, diabetic retinopathy, retinitis pigmentosa and any pathologic changes associated with the optic nerve;
  • Clinically significant corneal diseases;
  • Clinically significant/severe dry eye that would affect study measurements based on the investigator's expert medical opinion;
  • Previous intraocular or corneal surgery;
  • Pregnancy or lactation during study or planning to be pregnant/lactating;
  • Systemic medications that, in the opinion of the Investigator, may confound the outcome or increase the risk to the subject;
  • Other planned ocular surgical procedures;
  • Patients who desire monovision correction.
  • Other protocol-specified exclusion criteria may apply.

Key Trial Info

Start Date :

April 19 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 15 2023

Estimated Enrollment :

181 Patients enrolled

Trial Details

Trial ID

NCT04755231

Start Date

April 19 2021

End Date

March 15 2023

Last Update

October 10 2023

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

Peking University People's Hospital

Beijing, China, 100044

2

Beijing Tongren Hospital Capital Medical University

Beijing, China, 100730

3

Zhongshan Ophthalmic Center, Sun Yat-Sen University

Guandong, China, 510060

4

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, China, 310009